Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Table 3 The cut-offs of clinical and laboratorial parameters of SJIA patients treated Q4W

Parameter	OR (95%CI)	AUC** (95%CI)	p
Hemoglobin > 10.3 g/dl	32.0 (4.5; 227.2)	0.75 (0.57-0.88)	0.0001*
Granulocytes ≤ 9792 cells in 1 μl	24.8 (3.8; 160.0)	0.85 (0.68; 0.95)	0.0001*
WBC in 1 week ≤ 10.1*10⁹/l	6.9 (1.3; 37.2)	0.7 (0.49; 0.86)	0.027*
Granulocytes in 1 week ≤ 8142 cells in 1 μl	21.3 (2.9; 154.6)	0.82 (0.62-0.94)	0.001*
WBC in 2 weeks ≤ 7.5*10⁹/l	12.2 (2.1; 71.0)	0.66 (0.38; 0.88)	0.003*
Granulocytes in 2 weeks ≤ 3975 cells in 1 μl	28.0 (2.1; 379.3)	0.8 (0.52-0.96)	0.0015*
Platelets > 208 *10⁹/l	20.8 (2.0; 213.0)	0.64 (0.46; 0.8)	0.005*
CRP ≤ 82.2 mg/l	19.6 (3.3; 117.5)	0.77 (0.59-0.9)	0.001*
ESR ≤ 26 mm/h	28.4 (4.8; 168.3)	0.76 (0.58-0.89)	0.001*
Ferritin ≤ 605 mg/ml	89.9 (4.2; 1940.6)	0.86 (0.67-0.96)	0.0001*
LDH ≤ 571 U/l	42.0 (3.8; 469.1)	0.8 (0.58-0.94)	0.001*
Total protein > 7.2 g/dl	10.0 (1.1; 89.8)	0.75 (0.57-0.88)	0.027*
Albumin > 2.8 g/dl	46.0 (5.5; 382.7)	0.87 (0.7-0.96)	0.0001*
No splenomegaly	5.0 (1.1; 23.4)	-	0.05*
No hepatomegaly	31.8 (1.5; 659.6)	-	0.003
No coagulopathy	31.8 (1.5; 659.6)	-	0.005*
No ILD	20.8 (2.0; 213.0)	-	0.005*
No cardiac involvement	6.6 (1.3; 32.5)	-	0.04*
No CNS dysfunction	62.6 (3.1; 1282.9)	-	0.0001*
No kidney involvement	31.8 (1.5; 659.6)	-	0.005*
No MAS during TCZ	44.8 (2.2; 918.5)	-	0.01*

ISSN: 1546-0096